Study on the efficacy of Leptospira vaccines developed from serovars isolated from Trinidad and comparison with commercial vaccines using a hamster model

Vaccine

Volumn 28, Issue 33, 2010, Pages 5421-5426

  Suepaul, S M ^a   Carrington, C V ^a   Campbell, M ^a   Borde, G ^a   Adesiyun, A A ^a  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

Animal model; Leptospira; Leptospirosis; Vaccine

Indexed keywords

LEPTOSPIROSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE CARRIER; DOG; DRUG EFFICACY; DRUG SYNTHESIS; HAMSTER; HISTOPATHOLOGY; IMMUNOGENICITY; INFECTION PREVENTION; INOCULATION; KIDNEY HEMORRHAGE; KIDNEY TUBULE NECROSIS; LEPTOSPIRA; LEPTOSPIROSIS; LETHAL DOSE; LIVER INJURY; LUNG CONGESTION; LUNG HEMORRHAGE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SEROTYPE; STANDARDIZATION; TRINIDAD AND TOBAGO; VACCINATION; WHOLE CELL;

ANIMALS; BACTERIAL VACCINES; CRICETINAE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; LEPTOSPIRA; LEPTOSPIROSIS; MESOCRICETUS; MODELS, IMMUNOLOGICAL; SPECIES SPECIFICITY; TRINIDAD AND TOBAGO;

EID: 77955057497     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.019     Document Type: Article

References (45)

1. Levett P.N. Leptospirosis: a forgotten zoonosis?. Clinical and Applied Immunology Reviews 2004, 4(6):435-448.
2. World Health Organisation Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control: WHO Library Cataloguing-in Publication Data 2003.
3. Vanasco N.B., Sequeira M.D., Sequeira G., Tarabla H.D. Associations between Leptospiral infection and seropositivity in rodents and environmental characteristics in Argentina. Preventive Veterinary Medicine 2003, 60(1-2):227-235.
4. Meeyam T., Tablerk P., Petchanok B., Pichpol D., Padungtod P. Seroprevalence and risk factors associated with leptospirosis in dogs. Southeast Asian Journal of Tropical Medicine and Public Health 2006, 37(1):148-153.
5. Everard C.O.R., Fraser-Chanpong G.M., Bhagwandin L.J., Race M.W., James A.C. Leptospires in wildlife from Trinidad and Grenada. Journal of Wildlife Disease 1983, 19(3):192-199.
6. Everard C.O.R., Fraser-Chanpong G.M., James A.C., Butcher L.V. Serological studies on leptospirosis in livestock and chickens from Grenada and Trinidad. Transactions of the Royal Society of Tropical Medicine and Hygiene 1985, 79(6):859-864.
7. Meites E., Jay M.T., Deresinski S., Shieh W.J., Zaki S.R., Tompkins L. Reemerging diseases, California. Journal of Emerging Infectious Diseases 2004, 10(3):406-411.
8. Pappas G., Papadimitriou P., Siozopoulou V., Christou L., Akritidis N. The globalization of leptospirosis: worldwide incidence trends. Journal of Infectious Diseases 2008, 12(4):351-357.
9. Faine S. Leptospira and Leptospirosis 1994, CRC Press, Clayton, Victoria, Australia.
10. Farr R.W. Leptospirosis. Clinical Infectious Disease 1995, 21(1):1-8.
11. Andre-Fontaine G., Branger C., Gray A.W., Klaasen H.L. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Veterinary Record 2003, 153(6):165-169.
12. Sonrier C., Branger C., Michel V., Ruvoen-Clouet N., Ganiere J.P., Andre-Fontaine G. Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine 2001, 19(1):86-94.
13. Plank R., Dean D. Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans. Microbes and Infection 2000, 2(10):1265-1278.
14. Wang Z., Jin L., Wegrzyn A. Leptospirosis vaccines. Microbial Cell Factories 2007, 6(39):1-10.
15. Haake D.A., Mazel M.K., Mc Coy A.M., Milward F., Chao G., Matsunaga J., et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infection and Immunity 1999, 67(12):6572-6582.
16. Branger C., Chartrenet B., Gauvrit A., Aviat F., Aubert A., Bach J.M., et al. Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding haemolysin-associated protein 1. Infection and Immunity 2005, 73(7):4062-4069.
17. Koizumi N., Wantabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 2004, 22(11-12):1545-1552.
18. Matsuo K., Isogai E., Araki Y. Control of immunologically crossreactive Leptospiral infection by administration of lipopolysaccharides from a nonpathogenic strain of Leptospira biflexa. Microbiology and Immunology 2000, 44(11):887-890.
19. Jost B.H., Adler B., Faine S. Experimental immunisation of hamsters with lipopolysaccharide antigens and Leptospira interrogans. Journal of Medical Microbiology 1989, 29(2):115-120.
20. Adler B., Faine S. Immunogenicity of boiled compared with formalinized leptospiral vaccines in rabbits, hamsters and humans. Journal of Hygiene, London 1980, 84(1):1-10.
21. Chapman A.J., Adler B., Faine S. Antigens recognised by the human immune response to infection with Leptospira interrogans serovar hardjo. Journal of Medical Microbiology 1988, 25(4):269-278.
22. Hanson L.E., Tripathy D.N., Killinger A.H. Current status of leptospirosis immunization in swine and cattle. Journal of American Veterinary Medical Association 1972, 161(11):1235-1243.
23. Tripathy D.N., Hanson L.E., Nervig R.M., Cardella M.A., Mansfield M.E. Evaluation of the immune response of cattle to single and multiple vaccination with polyvalent bacterin. Proceedings from the Annual Meeting of US Animal Health Association 1976, (80):173-181.
24. Geisen V., Stengel C., Brem S., Muller W., Greene C., Hartmann K. Canine leptospirosis infections - clinical signs and outcome with different suspected Leptospira serogroups (42 cases). Journal of Small Animal Practice 2007, 48(6):324-328.
25. Marshall V., Kerr D.D. Early protection of dogs by a Leptospira bacterin. Modern Veterinary Practice 1974, 55(6):430-432.
26. Adesiyun A.A., Hull-Jackson C., Mootoo N., Halsal N., Bennett S., Clarke N.R., et al. Sero-epidemiology of canine leptospirosis in Trinidad: serovars, implications for vaccination and public health. Journal of Veterinary Medicine Series B Infectious Diseases Veterinary Public Health 2006, 53(2):91-99.
27. Haake DA. Hamster model of leptospirosis. Current protocol in Microbiology, 2006 September: Chapter: unit-12E.2.. doi:10.1002/9780471729259.mc.12e02s02.
28. Silva E.F., Santos C.S., Athanazio D.A., Seyffert N., Seixas F.K., Cerqueira G.M., et al. Characterization of virulence of Leptospira isolates in a hamster model. Vaccine 2008, 26(31):3892-3896.
29. Silva E.F., Medieros M.A., Mc Bride A.J.A., Matasunga J., Esteves G.S., Ramos J.G.R., et al. The terminal portion of leptospiral immunoglobulin-like protein Lig A confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007, 25(33):6277-6286.
30. Saha J.K., Xia J., Grondin J.M., Engle S.K., Jakubowski A. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Experimental Biology and Medicine 2005, 230(10):777-784.
31. Reed L.J., Muench H. A simple method of estimation fifty percent end-points. American Journal of Hygiene 1938, 27(3):493-497.
32. Freudenstein H., Hein B. Potency of Leptospiral vaccines and protection against chronic infection in golden hamsters. Comparative Immunology, Microbiology and Infectious Diseases 1991, 14(3):229-234.
33. KIT Biomedical Research International Course on Laboratory Methods for the Diagnosis of Leptospirosis 2006, Royal Tropical Institute, Amsterdam.
34. Hem A., Smith A.J., Solberg P. Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret, and mink. Laboratory Animal 1998, 32(February (4)):364-368.
35. Nunez J.F., Fajardo E.M., Perez E., Ontivero I., Silva D., Munoz P. Evaluation of two different potency tests for leptospirosis vaccine vax-spiral. Revista cubana de medicina tropical 2005, 57(1):67-68.
36. Falkow S. Molecular Koch's postulates applied to microbial pathogenicity. Review of Infectious Diseases 1988, 10(2):274-276.
37. Levett P.N., Morey R.E., Gallowway R.L., Turner D.E., Steigerwalt A.G., Mayer L.W. Detection of pathogenic leptospires by real-time quantitative real-time PCR. Journal of Medical Microbiology 2005, 54(1):45-49.
38. Croda J., Figueira C.P., Wunder E.A.J., Santos C.S., Reis M.G., Ko A., et al. Targeted mutagenesis in pathogenic Leptospira species: disruption of LigB gene does not affect virulence in animal models of leptospirosis. Infection and Immunity 2008, 76(12):5826-5833.
39. Chernukha IuG., Boroznov N.I., Ananina IuV. Populations of pathogenic Leptospira or varying virulence in nature. Journal of Microbiology, Epidemiology and Immunology 1988, (August (8)):13-16.
40. Marinho M., Oliveira-Junior I., Monteiro C.M.R., Perri S.H., Salomao R. Pulmonary disease in hamsters infected with Leptospira interrogans: histopathologic findings and cytokine mRNA expressions. American Journal of Tropical Medicine and Hygiene 2009, 80(5):832-836.
41. Miller N.G., Allen J.E., Wilson R. The pathogenesis of hemorrhage in the lung of the hamster during acute leptospirosis. Medical Microbiology and Immunology 1974, 160(4):269-278.
42. Nally J., Chantrannuwat C., Xiao-Yang W., Fishbein S., Pereira M.M., Pereira da Silva J.J., et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. American Journal of Pathology 2004, 163(4):1115-1127.
43. Srikram A., Wongratanacheewin S., Puapairroj A., Wutheikanun V., Sermsawan W. Analyses of vaccination protocols for Leptospira interrogans serovar Autumnalis in hamsters. American Journal of Tropical Hygiene 2008, 79(5):779-786.
44. Koizumi N., Wantabe H. Leptospirosis vaccines: past, present and future. Journal of Postgraduate Medicine 2005, 51(3):210-214.
45. Levett P.N. Leptospirosis. Clinical Microbiological Reviews 2001, 14(2):296-326.